DIAGENIC PARTNERS WITH DNAVision TO OFFER FIRST BREAST CANCER AND ALZHEIMER’S GENE-EXPRESSION BLOOD TESTS
OSLO. – November 28 2008 –DiaGenic ASA (OSL:DIAG) today announced that it has signed a service provider agreement with DNAVision, a leading panEuropean provider of gene expression-based diagnostic testing and services. With this laboratory service and following CE marking scheduled in early 2009, DiaGenic will be able to offer healthcare providers and patients in Europe its innovative blood-based gene-expression test for early detection of breast cancer and for Alzheimer’s disease in a CLIA/ISO17025 certified environment.
Joint press release from DNAVision and DiaGenic is enclosed.
MD PhD Erik Christensen, CEO
Telephone: +47 95939918